Skip NavigationSkip to Content

Identification of Vitronectin as an Extrinsic Inducer of Cancer Stem Cell Differentiation and Tumor Formation

  1. Author:
    Hurt, E. M.
    Chan, K.
    Serrat, M. A. D.
    Thomas, S. B.
    Veenstra, T. D.
    Farrar, W. L.
  2. Author Address

    [Hurt, Elaine M.; Duhagon Serrat, Maria Ana; Farrar, William L.] NCI, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA. [Chan, King; Veenstra, Timothy D.] NCI, Lab Prote & Analyt Technol, Frederick, MD 21701 USA. [Thomas, Suneetha B.] NCI, Basic Res Program, Sci Applicat Int Corp Frederick, Ctr Canc Res, Frederick, MD 21701 USA. [Duhagon Serrat, Maria Ana] Univ Republica, LIM F Ciencias, Montevideo, Uruguay.;Hurt, EM, NCI, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, 1050 Boyles St,Bldg 560,Room 21-81, Frederick, MD 21701 USA.;hurte@ncifcrf.gov
    1. Year: 2010
    2. Date: Mar 31
    3. Epub Date: 12/10/2009
  1. Journal: Stem Cells
    1. 28
    2. 3
    3. Pages: 390-398
  2. Type of Article: Article
  3. ISSN: 1066-5099
  1. Abstract:

    There is mounting evidence that tumors are initiated by a rare subset of cells called cancer stem cells (CSCs). CSCs are generally quiescent, self-renew, form tumors at low numbers, and give rise to the heterogeneous cell types found within a tumor. CSCs isolated from multiple tumor types differentiate both in vivo and in vitro when cultured in serum, yet the factors responsible for their differentiation have not yet been identified. Here we show that vitronectin is the component of human serum driving stem cell differentiation through an integrin alpha V beta 3-dependent mechanism. CSCs cultured on vitronectin result in downregulation of stem cell genes, modulation of differentiation markers, and loss of beta-catenin nuclear localization. Blocking integrin alpha V beta 3 inhibits differentiation and subsequently tumor formation. Thus, CSCs must be engaged by one or more extracellular signals to differentiate and initiate tumor formation, defining a new axis for future novel therapies aimed at both the extrinsic and intracellular pathways. STEM CELLS 2010; 28: 390-398

    See More

External Sources

  1. DOI: 10.1002/stem.271
  2. PMID: 19998373
  3. WOS: 000277093700002

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel